Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxetacaine + aluminium hydroxide + magnesium hydroxide is an oral pharmaceutical combination used primarily to treat symptoms of hyperacidity, heartburn, indigestion, gastritis, peptic ulcers, and gastroesophageal reflux disease (GERD). Aluminium hydroxide and magnesium hydroxide are antacids that neutralize excess gastric acid in the stomach. Oxetacaine is a local anesthetic that provides pain relief by numbing the gastric mucosa. This combination offers both rapid acid neutralization and symptomatic relief from pain or discomfort associated with acidic injury or ulcers. The product is available as suspensions or gels under various brand names[1][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxetacaine + aluminium hydroxide + magnesium hydroxide.